HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
Bionomics Analyst Ratings
Buy Rating Affirmed on Bionomics as BNC210 Enters Critical Phase 3 Trial for Social Anxiety Disorder
Bionomics Analyst Ratings
Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results
Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
Bionomics Analyst Ratings
Promising Progress of BNC210 Bolsters Buy Rating on Bionomics Amidst Rising Interest in SAD Treatments
Positive Phase 2b Study Results Bolster Buy Rating for Bionomics' PTSD Drug BNC210
Maxim Group Maintains Buy on Bionomics, Raises Price Target to $10
HC Wainwright & Co. Upgrades Bionomics to Buy, Announces $8 Price Target
Bionomics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (TVTX) and Bionomics (BNOX)
H.C. Wainwright Keeps Their Hold Rating on Bionomics (BNOX)
Loops Capital Adjusts Price Target on Bionomics to $17 From $10, Keeps Buy Rating
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Bionomics Analyst Ratings
Evercore ISI Group Downgrades Bionomics to In-Line, Lowers Price Target to $6
No Data